Diabetes:

Indications for NOVOLOG MIX 70/30:

Diabetes.

Adult:

For SC inj only. Onset 10–20mins, peak 1.8–3.6hrs, duration up to 24hrs.

Children:

Not established.

Contraindications:

During episodes of hypoglycemia.

Warnings/Precautions:

Do not reuse or share pens between patients; or needles and syringes when using vials. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hypo- or hyperglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Visual impairment. Renal or hepatic impairment. Pregnancy. Nursing mothers.

Interactions:

Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia. Do not mix with other insulins.

Adverse Reactions:

Hypoglycemia, hypokalemia, local inj site reactions, lipodystrophy, rash, pruritus, edema, sodium retention, weight gain; hypersensitivity and allergic reactions.

Generic Availability:

NO

How Supplied:

Vials (10mL)—1; FlexPen (3mL)—1